Skip to main content

Syros Pharmaceuticals, Inc.

SYRSDelisted Mar 10, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001556263

Syros Pharmaceuticals, Inc. was delisted on Mar 10, 2025; its insiders filed their last Form 4 on Dec 4, 2024; 44 institutions reported holding it in 13F filings for Q4 2024, worth $1.20M in total; no superinvestor held it.

Q4 2021 vs. Q3 2021

How the institutions holding Syros Pharmaceuticals, Inc. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021All holders in Q3 2021

13F holders of SYRS: Q3 2021 compared with Q4 2021
MeasureQ3 2021Q4 2021Change
Holders10090−10
Shares50.1M51.2M+1.05M (+2.1%)
Value$223.1M$166.0M−$57.1M (−25.6%)

New holders (12)

Institutions that held Syros Pharmaceuticals, Inc. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to SYRS in Q4 2021
InstitutionSharesValue% of portfolio
Bridgeway Capital Management, LLC170,000$554.0K0.01%
Federated Hermes, Inc.164,924$538.0K0.00%
Caxton Associates LP66,827$218.0K0.03%
Nomura Holdings Inc43,452$142.0K0.00%
Jump Financial, LLC26,100$85.0K0.01%
XTX Topco Ltd11,524$38.0K0.02%
Nisa Investment Advisors, LLC7,260$14.0K0.00%
Aquatic Capital Management LLC1,900$6.00K0.01%
CarsonAllaria Wealth Management, Ltd.1,626$5.00K0.00%
Quantbot Technologies LP1,300$4.00K0.00%
Allspring Global Investments Holdings, LLC361$1.00K0.00%
American Portfolios Advisors259$8440.00%

Sold out (22)

Institutions that held Syros Pharmaceuticals, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.